Section 232 Pharmaceutical Tariffs: What Life Sciences Importers Must Do Before July 31, 2026

The April 2, 2026 presidential proclamation imposing Section 232 tariffs on patented pharmaceutical imports did not give the life sciences industry much time to prepare. For covered importers, branded drug manufacturers, biologics CDMOs, specialty pharma companies, and clinical-stage developers importing patented drug substances and APIs from international contract manufacturing partners, the clock is running. Seventeen named large pharmaceutical companies face a July 31, 2026 effective date. All other covered importers face September 29, 2026. Between those two dates and today, life sciences supply chain leaders must make consequential compliance decisions: classify every imported product against the proclamation’s HTSUS provisions, determine which tariff tier applies, engage with Commerce Department onshoring plan requirements if seeking a reduced rate, and ensure that customs entries filed after the effective date reflect the correct tariff treatment.

The operational consequences of getting this wrong are not limited to unexpected duty costs. Incorrect HTSUS classification on a Section 232 entry creates post-summary correction liability, potential CBP audit exposure, and, in serious cases, penalty exposure under 19 U.S.C. §1592. For life sciences companies whose import programs have historically operated under near-zero duty rates backed by the 1994 WTO Pharma Agreement, Section 232 represents a structural break from the prior compliance environment. The companies best positioned to manage the transition are those that have already audited their import programs, confirmed the applicable tariff tier, and engaged a licensed customs broker with knowledge of the Section 232 regulatory framework.

THE REGULATORY FOUNDATION: WHAT SECTION 232 DOES AND WHY PHARMACEUTICALS ARE NOW SUBJECT TO IT

Section 232 of the Trade Expansion Act of 1962 authorizes the President to impose restrictions on imports when the Secretary of Commerce finds that those imports threaten to impair national security. The authority was historically used for metals, most prominently the 2018 steel and aluminum tariffs, and was not applied to pharmaceutical products during the first Trump administration, when medicines were explicitly excluded from broad tariff actions.

The 2026 proclamation marks the first time Section 232 authority has been applied to pharmaceuticals at scale. The White House finding cites the statistic that approximately 53% of patented medicines consumed in the United States are manufactured abroad, and that over 40% of global active pharmaceutical ingredient production is concentrated in China, as the national security basis for the action. The proclamation does not characterize the tariffs as a trade remedy in the conventional sense, it frames them as an industrial policy lever designed to accelerate domestic pharmaceutical manufacturing investment by removing the economic advantage of foreign production.

The legal structure matters for compliance purposes: because Section 232 tariffs are not subject to the same exclusion request procedures that apply to Section 301 tariffs, companies cannot petition for individual product-level exclusions the way they could for Chinese goods under the prior tariff regime. The available compliance pathways are those built into the proclamation itself: the MFN pricing agreement pathway, the Commerce-approved onshoring plan pathway, and the country-of-origin-based preferential rates.

WHO IS COVERED AND WHO IS EXEMPT: THE TARIFF TIERS IN DETAIL

The proclamation covers finished pharmaceutical products and active pharmaceutical ingredients classifiable under the Harmonized Tariff Schedule provisions listed in Annex I of the proclamation. The following table summarizes the tariff tier structure as it applies to life sciences importers:

The exemptions are specifically enumerated in the proclamation and are not discretionary. However, the generic exemption carries a critical qualification: the proclamation requires an annual review of the generic exclusion. For companies whose import programs include both branded and generic products, the classification distinction between “generic” and “patented” is not always straightforward, particularly for complex biological products where the innovator patent has recently expired and the product exists in a competitive biosimilar market.

THE COMPLIANCE DECISION TREE: FOUR PATHWAYS FOR COVERED IMPORTERS

Life sciences companies that have determined their imports are subject to Section 232 coverage face four practical compliance pathways, each with different cost, timeline, and administrative requirements.

1. ACCEPT THE STANDARD RATE AND REFLECT IN LANDED COST ANALYSIS

The most straightforward response for companies with limited import volume or whose commercial economics can absorb the incremental cost is to reclassify affected entries under the applicable Section 232 HTSUS heading and begin paying the 100% duty at the effective date. This pathway requires no Commerce Department engagement, no pricing agreement with HHS, and no onshoring commitment, only correct entry filing under the Annex I HTSUS codes. For companies importing small volumes of reference standards, controlled raw materials for analytical use, or drug substance for Phase 1 or 2 clinical programs where absolute duty liability is manageable, this may be the operationally simplest approach.

2. PURSUE COUNTRY-OF-ORIGIN-BASED PREFERENTIAL RATES

For companies whose manufacturing partners are located in the European Union, Japan, South Korea, or Switzerland, the 15% country-of-origin preferential rate applies without requiring an individual company agreement. The customs compliance requirement is accurate origin documentation: a valid certificate of origin or manufacturer’s declaration establishing the country where the pharmaceutical was manufactured or underwent its last substantial transformation. Life sciences companies with manufacturing networks in Ireland, the Netherlands, Germany, Switzerland, or Japan should verify that supply chain origin documentation is in order before the effective date.

3. APPLY FOR A COMMERCE-APPROVED ONSHORING PLAN

Companies willing to commit to U.S. manufacturing investments can apply to the Department of Commerce for an onshoring plan approval, reducing the tariff rate to 20% while the plan is implemented. For global CDMOs with existing or planned US operations, an onshoring plan that formalizes an already-planned US facility investment is a viable path to a reduced rate that does not require pricing concessions.

4. EXECUTE MFN PRICING AGREEMENT WITH COMBINED ONSHORING COMMITMENT

The zero-rate pathway, 0% tariff until January 20, 2029, requires both a Commerce-approved onshoring plan and a signed MFN pharmaceutical pricing agreement with HHS. This is the pathway that Pfizer and nine other large pharmaceutical companies executed in 2025 and early 2026. For mid-size specialty pharma companies or CDMOs, the MFN pricing pathway may carry commercial implications that outweigh the duty savings, particularly for companies with international commercial programs where price harmonization would reduce non-US revenue.

CUSTOMS CLASSIFICATION: THE FIRST AND MOST CONSEQUENTIAL STEP

Before any tariff pathway decision can be made, covered importers must complete a product-by-product classification review against the Annex I and Annex IV HTSUS codes specified in the proclamation. Classifying a covered product under the wrong heading and failing to collect the Section 232 duty creates underpayment liability that CBP may assess through a post-entry audit or CF-28 request for information. Conversely, over-classifying an exempt product, such as a biosimilar or cell therapy product, under a Section 232 heading and paying an unnecessary duty creates a refund claim requiring formal protest procedures under 19 U.S.C. §1514.

For biologics and specialty pharmaceutical products, classification is often not straightforward. A recombinant protein expressed in a CHO cell line may be classifiable under multiple HTSUS headings depending on its structural characteristics, therapeutic indication, and regulatory status (branded vs. biosimilar vs. orphan). Life sciences companies that previously relied on broadly applicable duty-free headings under WTO Pharma Agreement treatment should not assume that prior classification practices satisfy Section 232 requirements.

THE ONSHORING RESPONSE AND WHAT IT MEANS FOR US LOGISTICS INFRASTRUCTURE

The Section 232 tariff structure is explicitly designed to drive pharmaceutical manufacturing investment into the United States. Industry analysts have tallied $370 billion to $480 billion in announced US pharmaceutical manufacturing investment for the 2025 through 2030 period, including Eli Lilly’s $27 billion plan, Merck’s $70 billion US manufacturing commitment, Regeneron’s $2 billion New York site conversion, and Moderna’s $140 million investment in domestic mRNA production.

These investments are concentrated in API manufacturing, finished drug manufacturing, and fill-finish operations, the capital-intensive production tiers that Section 232 was designed to repatriate. What they do not directly address is the warehousing, distribution, and materials management infrastructure that commercial pharmaceutical operations require on a day-to-day basis. The onshoring of manufacturing capacity without corresponding investment in GMP-compliant US storage and distribution infrastructure does not produce a functional domestic supply chain, it produces a manufacturing node without the logistics ecosystem to support it.

For global CDMOs and international pharmaceutical manufacturers establishing or expanding US manufacturing operations, validated third-party storage and satellite materials management is the practical complement to owned manufacturing investment. An established US-based GMP logistics partner provides that infrastructure immediately, under a quality agreement that integrates with the client’s quality system, without the capital expenditure or timeline of owned facility development.

USE-CASE SCENARIOS

SCENARIO ONE: THE EUROPEAN BIOLOGICS CDMO WITH US MANUFACTURING EXPANSION

Scenario: A European biologics CDMO with manufacturing sites in Germany and Ireland imports drug substance and key starting materials into the US for client delivery and analytical testing. The CDMO’s imports of patented biologics drug substance were previously duty-free under WTO Pharma Agreement treatment. Under Section 232, EU-origin imports qualify for the 15% preferential rate, but customs entries filed before the July 31 effective date have not been updated to reflect the Section 232 HTSUS classification requirements. The CDMO is simultaneously announcing a US manufacturing facility investment that may support a Commerce onshoring plan application.

Euro-American’s licensed US Customs Brokerage reviews the CDMO’s import program, confirms the applicable Annex I HTSUS headings for each product, and ensures that customs entries filed after the effective date correctly reflect EU-origin 15% duty treatment. Simultaneously, Euro-American’s Worcester facility begins serving as the US-based GMP storage node for the CDMO’s incoming drug substance and raw material inventory, providing the domestic materials management footprint that supports the onshoring plan narrative and satisfies US distribution requirements.

SCENARIO TWO: THE SPECIALTY PHARMA COMPANY WITH ASIAN API SUPPLY

Scenario: A specialty pharmaceutical company developing a non-orphan, non-exempt patented small molecule imports its API from a contract manufacturer in India. The API does not qualify for any exemption under the proclamation. The standard 100% tariff rate applies at the September 29, 2026 effective date. The company’s cost-of-goods model did not anticipate a 100% ad valorem duty on the drug substance, and the VP of Supply Chain must assess whether to absorb the tariff, accelerate a US API sourcing program, or restructure the import arrangement.

Euro-American’s customs brokerage team conducts a classification audit to confirm the correct HTSUS heading, calculates the annual duty liability under the standard rate versus a potential 20% onshoring plan rate, and assesses whether the company’s planned US manufacturing partnerships could form the basis of a Commerce onshoring plan application. Euro-American also provides US-based GMP storage for the company’s finished product and commercial supply inventory, enabling consolidation of US warehousing and customs brokerage functions under a single GMP-qualified logistics partner.

SCENARIO THREE: THE US CDMO IMPORTING GMP EXCIPIENTS AND RAW MATERIALS

Scenario: A US-based CDMO manufacturing sterile injectable drug products imports pharmaceutical-grade excipients, specialized packaging components, and reference standards from European suppliers. A classification review reveals that certain specialized excipients and proprietary processing aids may be classifiable under Annex IV HTSUS codes for covered pharmaceutical ingredients. The CDMO needs confirmation of which products are subject to Section 232 treatment and which are outside the proclamation’s scope.

Euro-American’s customs brokerage team conducts a product-by-product classification review, separating exempt raw materials from covered pharmaceutical ingredients and establishing the correct HTSUS heading and applicable tariff rate for each product category. Euro-American’s GMP warehouse provides US-based storage for GMP-compliant excipients and packaging materials under validated CRT conditions, with ALCOA+-compliant receiving, inventory, and chain-of-custody documentation that integrates with the CDMO’s quality system and satisfies 21 CFR Part 211 requirements.

THE ROLE OF LICENSED CUSTOMS BROKERAGE IN SECTION 232 COMPLIANCE

The Section 232 pharmaceutical tariff regime creates immediate demand for licensed US Customs Brokerage expertise specific to the pharmaceutical and life sciences sector. The HTSUS classification requirements for pharmaceutical products, the distinction between patented and generic status for tariff purposes, the documentation requirements for country-of-origin-based preferential rates, and the interface between CBP customs entry procedures and Commerce Department onshoring plan applications all require a broker with working knowledge of both the pharmaceutical industry’s regulatory environment and the specifics of the Section 232 proclamation.

The customs brokerage function in a life sciences context is not separable from the materials management function. A customs entry that clears a shipment of biological drug substance must be followed immediately by validated cold chain handling, the product does not wait at ambient conditions while logistics handoffs are organized. The integration of licensed customs brokerage with GMP-compliant cold chain storage and temperature-controlled final-mile distribution minimizes excursion risk, chain-of-custody documentation gaps, and customs compliance errors at the critical interface between import clearance and GMP materials management.

Euro-American Worldwide Logistics operates licensed in-house US Customs Brokerage alongside its GMP cold chain and controlled-room-temperature storage infrastructure in Worcester, Massachusetts. The combination enables life sciences importers to clear pharmaceutical shipments under Section 232-compliant customs entries and immediately transfer them to validated GMP storage, under a single quality agreement, a single chain-of-custody documentation framework, and a single operational team that understands both the customs compliance requirements and the GMP materials management requirements of pharmaceutical-grade imports.

THE JUNE-TO-SEPTEMBER WINDOW: WHAT COVERED IMPORTERS SHOULD BE DOING NOW

The window between today and the July 31 and September 29 effective dates is narrow. Life sciences companies that have not yet begun their Section 232 compliance review are behind. The steps that should be completed before the applicable effective date include: a product classification audit against the proclamation’s HTSUS codes; an assessment of which tariff tier applies based on product category, country of origin, and any existing MFN pricing or onshoring plan agreements; engagement with a licensed customs broker to update entry filing procedures; and a review of origin documentation, certificates of origin, manufacturer’s declarations, required to substantiate the applicable rate.

For companies whose analysis reveals that the standard 100% rate applies and whose annual duty liability is significant, the onshoring plan pathway should be evaluated against existing US manufacturing investment intentions. The Commerce Department has not published a formal processing schedule for onshoring plan approval, which means companies seeking the 20% reduced rate by the effective date must move immediately.

Life sciences importers seeking to understand their Section 232 exposure and ensure compliant customs entries before the July 31, 2026 effective date should contact Euro-American Worldwide Logistics, licensed in-house US Customs Brokerage, integrated with GMP cold chain storage and distribution, 40 miles west of Boston.